Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.

• Material Type: 博士論文
• Title: Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis.
• Author/Editor: Fujinaga, Yukihisa; Kawaratani, Hideto; Kaya, Daisuke; Tsuji, Yuki; Ozutsumi, Takahiro; Furukawa, Masanori; Kitagawa, Koh; Sato, Shinya; Nishimura, Norihisa; Sawada, Yasuhiko; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
• Author Heading: Fujinaga, Yukihisa; Kawaratani, Hideto; Kaya, Daisuke; Tsuji, Yuki; Ozutsumi, Takahiro; Furukawa, Masanori; Kitagawa, Koh; Sato, Shinya; Nishimura, Norihisa; Sawada, Yasuhiko; Takaya, Hiroaki; Kaji, Kosuke; Shimozato, Naotaka; Moriya, Kei; Namisaki, Tadashi; Akahane, Takemi; Mitoro, Akira; Yoshiji, Hitoshi
• Publication, Distribution, etc.: MDPI
• Publication Date: 2020-08-04
• Publication Date (W3CDTF): 2020-08-04
• Alternative Title: ラットを用いた非アルコール生脂肪肝炎におけるアンジオテンシンⅡ受容体拮抗薬とリファキシミン併用薬投与による肝線維化抑制効果の検討
• Periodical title: International journal of molecular sciences
• No. or year of volume/issue: 21 15
• Volume: 21
• Issue: 15
• Pages: Article No.5589-
• ISSN (Periodical Title): ISSN : 1422-0067
• Degree grantor/type: 奈良県立医科大学
• Date Granted: 2021-03-15
• Dissertation Number: 甲第780号
• Degree Type: 博士（医学）
• Text Language Code: eng
• Subject Heading: hepatic fibrosis; rifaximin; ARB; metabolic syndrome; NASH
• Target Audience: 一般
• Note (General): type:Thesis; The progression of nonalcoholic steatohepatitis (NASH) is complicated. The multiple parallel-hits theory is advocated, which includes adipocytokines, insulin resistance, endotoxins, and oxidative stress. Pathways involving the gut-liver axis also mediate the progression of NASH. Angiotensin-II receptor blockers (ARB) suppress hepatic fibrosis via the activation of hepatic stellate cells (HSCs). Rifaximin, a nonabsorbable antibacterial agent, is used for the treatment of hepatic encephalopathy and has been recently reported to improve intestinal permeability. We examined the inhibitory effects on and mechanism of hepatic fibrogenesis by combining ARB and rifaximin administration. Fischer 344 rats were fed a choline-deficient/l-amino acid-defined (CDAA) diet for 8 weeks to generate the NASH model. The therapeutic effect of combining an ARB and rifaximin was evaluated along with hepatic fibrogenesis, the lipopolysaccharide-Toll-like receptor 4 (TLR4) regulatory cascade, and intestinal barrier function. ARBs had a potent inhibitory effect on hepatic fibrogenesis by suppressing HSC activation and hepatic expression of transforming growth factor-β and TLR4. Rifaximin reduced intestinal permeability by rescuing zonula occludens-1 (ZO-1) disruption induced by the CDAA diet and reduced portal endotoxin. Rifaximin directly affect to ZO-1 expression on intestinal epithelial cells. The combination of an ARB and rifaximin showed a stronger inhibitory effect compared to that conferred by a single agent. ARBs improve hepatic fibrosis by inhibiting HSCs, whereas rifaximin improves hepatic fibrosis by improving intestinal permeability through improving intestinal tight junction proteins (ZO-1). Therefore, the combination of ARBs and rifaximin may be a promising therapy for NASH fibrosis.; 博士（医学）・甲第780号・令和3年3月15日; © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).; identifier:International journal of molecular sciences Vol.21 No.15 Article No.5589 (2020 Aug); identifier:14220067; identifier:http://ginmu.naramed-u.ac.jp/dspace/handle/10564/3904; identifier:International journal of molecular sciences, 21(15): Article No.5589
• Source: fulltext; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3904/1/01%e7%94%b2780%e6%9c%ac%e6%96%87%e3%81%ae%e8%a6%81%e6%97%a8.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3904/2/02%e7%94%b2780%e5%af%a9%e6%9f%bb%e8%a6%81%e6%97%a8.pdf; http://ginmu.naramed-u.ac.jp/dspace/bitstream/10564/3904/3/03%e7%94%b2780%e6%9c%ac%e6%96%87.pdf
• Access Restrictions: インターネット公開
• Related Material (DOI): 10.3390/ijms21155589
• Periodical Title (NCID): AA12038549; https://ci.nii.ac.jp/ncid/AA12038549
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 奈良県立医科大学 : 奈良県立医科大学機関リポジトリ GINMU